Diagnostic Radiopharmaceuticals 
for TheranosticsPETNET Solutions provides essential PET diagnostic radiopharmaceuticals for effective theranostics

Appropriate patient selection is key to optimizing patient outcomes. For example, the use of PSMA-targeted therapy will only be effective against tumor lesions with sufficient expression of the target receptor.

Emerging data has shown the superiority of PSMA imaging with PET/CT over conventional imaging for primary diagnoses. Single photon emission computed tomography (SPECT) is more available worldwide, and the imaging agent is low in cost.¹ The pattern of tumor PSMA expression should be evaluated per molecular imaging (preferred: 68Ga/18F-PSMA PET; alternatively: 99mTc-PSMA SPECT)²

In this case, a comprehensive evaluation of initial metastatic burden a pre-therapy 18F-PSMA PET scan displayed significant burden of PSMA-avid abdominopelvic and mediastinal nodal metastases.  

^{Data courtesy of University Hospital Heidelberg, Heidelberg, Germany.}

Once the extent of disease has been confirmed 177Lu-PSMA therapy was given with post therapy planar imaging following each cycle. 

¹⁸F-PSMA PET performed 1 year following therapy shows complete response to therapy with absence of PSMA-avid disease